Active Ingredient(s): Fluciclovine
FDA Approved: * May 27, 2016
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Axumin Overview

Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC),[1][2] or as Axumin (brand name), and colloquially as anti-3[18F] FACBC or F18, is a diagnostic agent "indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels."[3][4] Contents 1 Background 2 Mechanism 3 Marketing 4 References 5...

Read more Axumin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Axumin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 335-8200 Mbq/ml (9-221 Mci/ml)
  • Solution: 9-221mci/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Axumin: (1 result)

Sorted by National Drug Code
  • 69932-001 Axumin 221 mci/Ml Intravenous Injection, Solution by Blue Earth Diagnostics

Other drugs which contain Fluciclovine or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 May 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA